Keyword: Takeda

In a phase 3 trial of Ninlaro as a first-line maintenance treatment in multiple myeloma, patients experienced significant survival benefits.

Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.

Takeda has yet to seek approval for its vaccine candidate to treat dengue, but it now has a  €130 million plant and 200 jobs relying on that nod. 

In the largest acquisition in Stada's history, the German generics maker is laying out $660M for 20 Takeda drugs in the Commonwealth states.

Takeda's rare disease sales dropped sharply. Astellas teamed with Pandion on Type 1 diabetes. Shanghai's I-Mab filed for a $100 million Nasdaq IPO.

Worries about competition to Shire's bread-and-butter hemophilia franchise were clear even before Takeda bought it. That fear has become reality.

FTC review delays Sandoz-Aurobindo generics deal. Manufacturing questions push back Zolgensma decision in Japan. AZ expects mid-teens China growth.

AZ and Daiichi's antibody-drug conjugate nabs FDA priority review; FDA shames Torrent for tainted heart drugs; Takeda sells emerging markets drugs.

In a $200 million buy, emerging markets-focused Swiss pharma Acino International will pick up about 30 Takeda products in the Middle East and Africa.